
News|Videos|February 20, 2026
María Teresa Bourlon, MD, MS, FASCO, previews practice-changing research at ASCO GU 2026
Author(s)María Teresa Bourlon, MD, MS, FASCO
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Bourlon outlines what to watch for in prostate, urothelial, kidney, and testicular cancer.
Advertisement
Advertisement
In this preview of research expected at the 2026 ASCO Genitourinary Cancers Symposium, medical oncologist María Teresa Bourlon, MD, MS, FASCO, outlined major clinical advances anticipated across prostate, urothelial, kidney, and testicular cancers. Speaking from her practice at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, she emphasized that the meeting will focus heavily on survival outcomes, biomarker-guided therapy, and emerging treatment mechanisms.
Related to this article

Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.

William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.

Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.

Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Advertisement
Advertisement

